Gilead Sciences (GILD) Competitors

Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, community ranking, analyst recommendations, earnings and valuation.

Which has stronger valuation & earnings, GILD or AMGN?

Amgen has lower revenue, but higher earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$27.28B	3.46	$4.59B	$4.35	17.44
Amgen	$26.32B	5.46	$6.55B	$14.83	18.10

Is GILD or AMGN a better dividend stock?

Gilead Sciences pays an annual dividend of $3.00 per share and has a dividend yield of 4.0%. Amgen pays an annual dividend of $8.52 per share and has a dividend yield of 3.2%. Gilead Sciences pays out 69.0% of its earnings in the form of a dividend. Amgen pays out 57.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Do analysts recommend GILD or AMGN?

Gilead Sciences currently has a consensus price target of $90.05, suggesting a potential upside of 19.09%. Amgen has a consensus price target of $265.44, suggesting a potential downside of 0.85%. Given Gilead Sciences' stronger consensus rating and higher possible upside, research analysts clearly believe Gilead Sciences is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.50
Amgen	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.40

Does the media favor GILD or AMGN?

In the previous week, Amgen had 10 more articles in the media than Gilead Sciences. MarketBeat recorded 21 mentions for Amgen and 11 mentions for Gilead Sciences. Amgen's average media sentiment score of 0.92 beat Gilead Sciences' score of 0.82 indicating that Amgen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Amgen	13 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Is GILD or AMGN more profitable?

Amgen has a net margin of 30.02% compared to Gilead Sciences' net margin of 20.03%. Amgen's return on equity of 196.60% beat Gilead Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	20.03%	37.53%	12.66%
Amgen	30.02%	196.60%	12.42%

Do insiders and institutionals hold more shares of GILD or AMGN?

82.3% of Gilead Sciences shares are owned by institutional investors. Comparatively, 74.4% of Amgen shares are owned by institutional investors. 0.2% of Gilead Sciences shares are owned by company insiders. Comparatively, 0.6% of Amgen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Which has more risk and volatility, GILD or AMGN?

Gilead Sciences has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.

Does the MarketBeat Community prefer GILD or AMGN?

Gilead Sciences received 942 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 77.74% of users gave Gilead Sciences an outperform vote while only 72.80% of users gave Amgen an outperform vote.

Company	Underperform	Outperform
Gilead Sciences	Outperform Votes 2438 77.74%	Underperform Votes 698 22.26%
Amgen	Outperform Votes 1496 72.80%	Underperform Votes 559 27.20%

Summary

Amgen beats Gilead Sciences on 11 of the 20 factors compared between the two stocks.